INTRODUCTIONHeart failure (HF) is a pivotal public health issue which influences over 5.7 million American people and takes $37.2 billion every year and its morbidity reaches epidemic proportions. Moreover, it is evaluated that 45% of women and 59% of men die in 5 years after a HF diagnosis. Chronic HF (CHF) is a long‐term product of heart failure, is usually managed by treating symptoms and patients suffering from deteriorating symptoms and signs may need hospitalization or more frequent doctor visits. The most common causes of HF are as follow: coronary artery disease, high blood pressure, atrial fibrillation, previous myocardial infarction (heart attack), valvular heart disease, cardiomyopathy, infection, and excessive alcohol consumption. The prevalence and occurrence of HF progressively increases with age, with the most affected age group being over 50 years. In developed countries, 1%‐2% of the adult population suffers from HF, increasing to ≥10% for those older than 70 years. The National Institute for Health and Care Excellence (NICE) recommends measurement of brain natriuretic peptide combined with an ultrasound of the heart in the occurrence of symptom development. Up until now no elite diagnostic criterion has been established for HF.Suppression of tumorigenicity 2 (ST2), namely an interleukin (IL)‐33 related receptor, is
Journal of Clinical Laboratory Analysis – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud